Menopausal Hormone Therapy
Menopausal hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. Long-term Women's Health Initiative follow-up (Manson 2017, JAMA) found no increase in all-cause mortality over 18 years, and current consensus holds that for healthy women under 60 or within 10 years of menopause onset, benefits generally outweigh risks — with individualized, physician-supervised decision-making.
Written/Reviewed by: Dr. Michael Ellis, DO — Medical Director
Scientific/Technical contribution: John Campetella
Last medical review: June 2026
How the evidence evolved
The 2002 WHI publication triggered a collapse in hormone-therapy use based on risks observed in an older-skewing cohort. Subsequent age-stratified analyses and 18-year cumulative follow-up showed neutral all-cause mortality and a far more favorable profile for younger, recently menopausal women — the basis of the 'timing hypothesis'.
Current consensus
The North American Menopause Society's position statement supports hormone therapy as first-line for moderate-to-severe vasomotor symptoms in appropriate candidates, with formulation, dose, route and duration individualized to each woman's risk profile and goals.
Limitations
Risk profiles differ by age, time since menopause, formulation and route (transdermal vs oral). Breast cancer risk with combined therapy is duration-dependent and must be reviewed individually. Hormone therapy is not indicated solely for prevention of chronic disease.
The Integrated Wellness approach
We map the full hormonal picture — estradiol, progesterone, FSH, thyroid, cortisol rhythm and metabolic context — account for cycle phase and life stage, and have licensed clinicians walk through the evidence-based options rather than a one-size-fits-all protocol.
A = consistent RCT/meta-analytic · B = strong observational/mixed · C = limited · Emerging = active research
- Manson JE, et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality (WHI). JAMA.
- Rossouw JE, et al. (WHI Investigators) (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA.
- The North American Menopause Society (2022). The 2022 hormone therapy position statement. Menopause.